Baird analyst Eric Coldwell raised the firm’s price target on Medpace to $233 from $226 and keeps a Neutral rating on the shares. The analyst said once again, the company highlighted weakness in internal metrics and emphasized client funding challenges while using terms such as "downturn." This commentary comes while they experience dominant fundamentals so with admitted frustration, Baird remains on the sidelines.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MEDP: